Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study

Arthritis and Rheumatism
D O CleggW G Henderson

Abstract

To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3% for SSZ treatment compared with 47.7% for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.

References

Jan 1, 1987·Scandinavian Journal of Rheumatology. Supplement·K TrnavskýJ Vácha
Jan 1, 1988·Scandinavian Journal of Rheumatology·M Ostensen
Aug 1, 1986·Annals of the Rheumatic Diseases·A Calin
Nov 1, 1985·Seminars in Arthritis and Rheumatism·E V Lally, G Ho

❮ Previous
Next ❯

Citations

Apr 6, 2013·Clinical Rheumatology·Terhi M UotilaUNKNOWN Pirkanmaa Waterborne Outbreak Study Group
Jul 26, 2000·Current Opinion in Rheumatology·R D InmanA P Hudson
May 7, 2010·Current Opinion in Rheumatology·John D Carter, Alan P Hudson
Apr 9, 2010·International Journal of Rheumatic Diseases·Mohammad-Bagher Owlia, Adrian R Eley
Apr 16, 2004·Clinical Microbiology Reviews·Inés ColmegnaLuis R Espinoza
Jun 30, 2000·Annals of the Rheumatic Diseases·T Yli-KerttulaA Toivanen
Jul 11, 2006·Postgraduate Medical Journal·S S HamdulayA Keat
Feb 1, 2010·Therapeutic Advances in Musculoskeletal Disease·John D Carter
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·M RudwaleitJ Sieper
Feb 27, 2013·International Journal of Clinical Rheumatology·John D CarterAlan P Hudson
Dec 4, 2013·Annals of the Rheumatic Diseases·Henning Zeidler, Alan P Hudson
Dec 24, 2005·Expert Opinion on Investigational Drugs·Carlo PalazziIgnazio Olivieri
Mar 1, 2006·Expert Opinion on Pharmacotherapy·Giorgia Martini, Francesco Zulian
Oct 1, 2005·Scandinavian Journal of Rheumatology·M Leirisalo-Repo
Nov 22, 2011·Best Practice & Research. Clinical Rheumatology·John D Carter, Robert D Inman
Nov 22, 2011·Best Practice & Research. Clinical Rheumatology·Timo Hannu
Feb 3, 1999·Baillière's Clinical Rheumatology·H R Schumacher, T Bardin
Nov 28, 2006·Best Practice & Research. Clinical Rheumatology·Markus RihlJens G Kuipers
Feb 24, 2016·Clinics in Dermatology·Karolyn A WanatMisha Rosenbach
Apr 3, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Elizabeth Carlin, Sarah Flew
Dec 19, 2003·Expert Opinion on Pharmacotherapy·Carlo PalazziAttilio Petricca
May 5, 2001·Expert Opinion on Pharmacotherapy·F D KeyserE M Veys
Sep 15, 2016·Expert Review of Clinical Immunology·John D Carter, Alan P Hudson
Mar 16, 2017·Infectious Disease Clinics of North America·Steven K Schmitt
May 16, 2017·Internal Medicine·Kazuya HondaKiyoshi Migita
Apr 26, 2008·Journal of the American Academy of Dermatology·Ines B Wu, Robert A Schwartz
Aug 1, 1997·Rheumatic Diseases Clinics of North America·R Burgos-VargasJ Vázquez-Mellado
Jun 30, 2014·International Journal of STD & AIDS·E M CarlinM Janier
Oct 9, 2001·International Journal of STD & AIDS·E M CarlinUNKNOWN European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Healt
Jan 27, 2006·World Journal of Gastroenterology : WJG·Silvio DaneseAntonio Gasbarrini
May 16, 2013·Journal of Cutaneous Medicine and Surgery·Amrinder J Kanwar, Rahul Mahajan
Apr 19, 2018·BMJ Case Reports·Patrick HoverstenAnjali Bhagra
May 2, 2007·Arthritis and Rheumatism·Jasvinder A SinghSiamak Noorbaloochi
Mar 11, 2010·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Mihir D WechalekarCatherine L Hill
Nov 26, 2013·The British Journal of Dermatology·W H BoehnckeA B Gottlieb
Oct 17, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Ljiljana Pavlica
May 28, 2020·Current Rheumatology Reports·Daniel WendlingFrank Verhoeven
Mar 10, 2001·Hospital Medicine·N Hopkinson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.